Riverwater Companions, an funding administration firm, launched its “Small Cap Technique” Q1 2026 investor letter. A duplicate of the letter might be downloaded right here. In Q1 2026, the Riverwater Small Cap Technique outperformed the Russell 2000 Index. The quarter rewarded endurance and self-discipline. The primary quarter of 2026 noticed a big shift in market management and threat perceptions, attributable to geopolitical tensions within the Center East and considerations over sustainable progress within the software program and AI sectors. Moreover, personal credit score markets are beneath stress. On this setting, the agency is concentrating on figuring out market dislocations attributable to what it perceives as indiscriminate promoting, notably in AI-related areas. As well as, please verify the Technique’s prime 5 holdings to know its greatest picks in 2026.
In its first-quarter 2026 investor letter, Riverwater Companions Small Cap Technique highlighted shares like AtriCure, Inc. (NASDAQ:ATRC). AtriCure, Inc. (NASDAQ:ATRC) is a medical gadget firm centered on the event and manufacture of applied sciences for the surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and short-term ache administration. On Could 4, 2026, AtriCure, Inc. (NASDAQ:ATRC) closed at $28.78 per share. One-month return of AtriCure, Inc. (NASDAQ:ATRC) was 0.17%, and its shares misplaced 3.05% over the previous 52 weeks. AtriCure, Inc. (NASDAQ:ATRC) has a market capitalization of $1.46 billion.
Riverwater Companions Small Cap Technique acknowledged the next relating to AtriCure, Inc. (NASDAQ:ATRC) in its Q1 2026 investor letter:
“AtriCure, Inc. (NASDAQ:ATRC) underperformed in the course of the first quarter of 2026 regardless of delivering a powerful earnings report and offering 2026 steering that got here in above road expectations, reflecting continued momentum throughout its core atrial fibrillation and appendage administration companies. The inventory’s weak spot was pushed much less by fundamentals and extra by a shift in investor sentiment following Edwards Lifesciences’ announcement of a competing surgical left atrial appendage closure (LAAC) product, which can straight compete with AtriCure’s AtriClip franchise. This growth created an overhang on the shares, as buyers reassessed the sturdiness of AtriCure’s market management in appendage administration. Nonetheless, Edwards’ product just isn’t anticipated to be totally obtainable till late in 2026 or 2027, whereas AtriCure’s AtriClip is already nicely established and broadly adopted amongst cardiac surgeons, supported by sturdy scientific knowledge and entrenched doctor relationships. In our view, the sell-off displays near-term aggressive considerations somewhat than a deterioration within the firm’s underlying progress trajectory, and AtriCure stays nicely positioned given its first-mover benefit and deep integration inside surgical workflows.”
